Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation aimed at addressing unmet global needsSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has received an approximately $3.6 million payment under an exist ...

Financial Data and Key Metrics Changes - The company ended Q3 2025 with approximately $23 million in cash and cash equivalents and working capital of approximately $3.8 million [21] - During Q3, the company received approximately $18.7 million in net proceeds from sales of common stock and a total of $7.3 million in grant payments, strengthening its balance sheet [21] - General and administrative (G&A) expenses were $2.5 million compared to $2 million in Q3 2024, primarily due to increases in professional services and commercial readiness expenses [22] - Research and development (R&D) expenses were $1.2 million compared to $2.7 million in Q3 2024, a 56% decrease, attributed to non-dilutive funding and reduced manufacturing costs [22] Business Line Data and Key Metrics Changes - The company is on track to support the commercial availability of Dare to Play Sildenafil Cream through a 503(b) outsourcing facility before the end of 2025, marking a significant milestone in women's sexual health [5][11] - The Dare to Restore product line, which includes proprietary vaginal probiotic products, is expected to be available in the U.S. in Q1 2026 [15] - The company is also pursuing a combination estradiol and progesterone intravaginal ring branded as Dare to Reclaim, targeting early 2027 for availability [16] Market Data and Key Metrics Changes - The company is addressing significant unmet needs in women's health, including contraception, HPV infection, and preterm birth, through its clinical pipeline [5][17] - The estimated market for compounded hormone therapy is $4.5 billion, with Dare to Reclaim positioned as a unique solution in this space [16] Company Strategy and Development Direction - The company employs a dual-path strategy, commercializing proprietary formulations while pursuing FDA approval and advancing select solutions as branded consumer health products [2][5] - The focus is on bridging the gap between promising science and real-world solutions for women, leveraging non-dilutive capital and disciplined investment strategies [6][17] - The company aims to create a self-reinforcing ecosystem for growth through its commercial initiatives, enhancing brand awareness and provider engagement [16][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recent FDA guidance on hormone replacement therapy, which aligns with the company's development of Dare to Reclaim [24][28] - The company is excited about the potential of Dare to Play Sildenafil Cream as a near-term revenue driver and anticipates initial revenue recognition in Q4 2025 [39][40] - The management believes that the women's health market is ripe for value creation due to its historical underfunding and underserved status [40] Other Important Information - The company is actively recruiting for its pivotal phase III study of Oviprene, a contraceptive product, with completion anticipated in 2026 [17][18] - The company has received significant grant funding to support various programs, including DARE HPV and DARE LARK 1, demonstrating its ability to leverage strategic collaborations [20] Q&A Session Summary Question: Can you comment on FDA's recent reversal and guidance on hormone replacement therapy in menopause? - Management expressed excitement about the FDA's change and highlighted the development of Dare to Reclaim, a hormone therapy vaginal ring that combines estradiol and progesterone [24][25] Question: Will Dare to Reclaim be available through a compounder or is there a path for FDA approval? - Management confirmed that both paths are being pursued, similar to the strategy for Dare to Play Sildenafil Cream [29] Question: How is the company prioritizing R&D programs for FDA approval? - The focus is on advancing Dare to Play, Dare to Reclaim, and grant-funded programs like Oviprene and DARE HPV, prioritizing those with clear regulatory pathways [30][32] Question: What partnerships are being considered to increase awareness for Dare to Play? - Management mentioned plans for clinician awareness initiatives and online advertising, as well as partnerships with telehealth resources to facilitate prescription fulfillment [33][36] Question: Is there additional capacity left on the ATM? - Management indicated that the company is subject to baby shelf limitations, which restrict the amount available under the ATM [38]

Core Insights - Daré Bioscience is hosting a webinar on November 17, 2025, to discuss its innovative product DARE to PLAY™, a topical sildenafil cream designed specifically for women [1][2] - DARE to PLAY™ is the first evidence-backed sildenafil cream for women, showing increased genital blood flow within 10 to 15 minutes of application and improvements in arousal sensations [2][3] - The product is expected to be commercially available through a 503B outsourcing facility by the end of 2025, marking a significant advancement in women's sexual health solutions [2][3] Company Overview - Daré Bioscience focuses on addressing gaps in women's health through science-based solutions, with a commitment to rigorous clinical research and development [4][5] - The company aims to provide credible, evidence-based therapies for various women's health issues, including sexual health, menopause, and fertility [4][5] - Daré is a female-led organization recognized for its contributions to innovation and advocacy in women's health, with leadership acknowledged in industry publications [6] Product Details - DARE to PLAY™ is a unique formulation that enhances genital blood flow and arousal response, supported by FDA-reviewed clinical data [2][3] - The product's anticipated launch will be the first time a topical sildenafil formulation manufactured under cGMP requirements is available to healthcare providers [2][3] - The webinar will feature expert clinicians discussing the product's benefits and clinical data, providing an opportunity for participants to join a product alert list [3]

[Music] Vagina. Vagina. Yes, I said it in front of you all on a stage into a microphone. And guess what? The world didn't end. But let's be honest, some of you flinched. Some of you looked down. And some of you might be still wanting this to turn into a joke. >> It won't. I say it every day. I'm a doctor. I'm an aesthetic gynecologist. And I talk about vaginas all day. Not in secrecy, not in shame, not in whisper, not as something dirty, embarrassing or as a taboo. I am an aesthetic gynecologist. I talk abo ...

Core Insights - Daré Bioscience, Inc. is focused on addressing women's health issues by bridging the gap between scientific advancements and practical solutions [3][4] - The company will host a conference call on November 13, 2025, to discuss its financial results for Q3 2025 and provide updates [1] Company Overview - Daré Bioscience is dedicated to developing innovative solutions in women's health, including areas such as contraception, menopause, pelvic pain, fertility, vaginal health, and infectious diseases [3] - The company emphasizes the importance of rigorous scientific research and clinical validation in its product development [4] Industry Context - Historically, women's health innovations have been underfunded and delayed, with many women advised to "wait it out" regarding health issues [4] - There is a growing awareness and conversation around women's health topics, but access to evidence-based solutions remains insufficient [4] Leadership and Recognition - Daré Bioscience's leadership has received accolades for their contributions to women's health innovation, including recognition on Medicine Maker's Power List and Endpoints News' Women in Biopharma [5] - The CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma [5]

Problem Statement & Feminist Perspective - Globally, one in three people lack access to basic sanitation [3] - Women spend over 98 billion hours annually seeking safe places to relieve themselves [3] - Lack of access to toilets is a feminist issue, impacting girls' futures, safety, and autonomy [3] - Toilets are about voice, presence, power, dignity, and access, yet rarely discussed in feminism [8] - Feminist sanitation justice addresses privacy, shame, and safety, not just infrastructure [11] Business & Social Impact Initiatives - A social impact business was launched to maintain toilet cleanliness, hiring women and selling advertising, but failed due to taboo [4] - Jeet, a movement, was launched to remove obstacles for women and girls [5] - Jeet advocated for the removal of tax on sanitary pads and remodeled school toilets [6] - Dignity kits with reusable sanitary napkins were designed to keep girls in school for up to two years [6] Education & Health Consequences - Girls miss up to 100 days of school annually due to lack of toilets and menstrual hygiene [7] - UNESCO confirms girls are more likely to drop out after puberty if schools lack toilets [7] - Lack of access leads to early marriage, domestic servitude, and exploitation [7] - Holding it in due to lack of toilet doors leads to dehydration, urinary tract infection, and kidney disease [9][10] Solutions & Recommendations - WASH (water, sanitation, and hygiene) should be reimagined as a feminist frontier, centering women's bodies and stories [12] - Address the "missing door" and listen to women's needs to achieve UN Sustainable Development Goal 6 [12] - Making sanitation a feminist issue is disruptive because toilets are about voice, presence, access, and power [13]

This is a big issue. We've been talking about it for years, about the amount of money that's either shifting into the hands of women. What it means, what the differences are.I am curious, and maybe not everybody's aware of all the work that you guys are doing. You have this very specific mission at Pivotal. Remind everybody what you're up to, and I am curious about what it means on a day to day basis, what you're looking forward to invest in relationships and so on.Yes. Again, well, thank you for having me. ...

Core Insights - LifeMD, Inc. has appointed Dr. Tara Scott as ambassador and clinical advisor for its women's health program, focusing on areas such as perimenopause, menopause, hormonal balance, and long-term wellness [1][3][6] Company Commitment - The appointment of Dr. Scott reflects LifeMD's dedication to creating a comprehensive women's health offering, addressing underdiagnosed and underserved medical aspects [3][4] Program Features - LifeMD's virtual women's health program includes: - Virtual consultations combining clinical expertise, personalized therapies, and lifestyle strategies for long-term health [5] - A holistic approach with tiered subscriptions, including lab access, mail-order prescriptions, and dietitian support [5] - LifeMD+ membership providing 24/7 urgent and primary care access, prescription renewals, and a marketplace of wellness products [5] Dr. Scott's Expertise - Dr. Scott is a board-certified obstetrician/gynecologist and menopause specialist with over 25 years of experience, recognized for her research-backed hormonal balancing strategies [6][7] Market Opportunity - Women's health, particularly menopause and osteoporosis, remains underserved, with only 25% of women seeking treatment for menopause-related symptoms and over two-thirds of osteoporosis cases undiagnosed [7] - The projected market opportunity for menopause and osteoporosis is estimated to be $60-70 billion by 2030, significantly larger than current market size [7]

Women's Health & Funding - Less than 1% of funding is spent on women over 40 [3] - Women live 20% more of their lives with chronic disease or mental health disorders [3] - 50% of patients with unexplained infertility have endometriosis [3] - It takes women 7 to 10 years to get an endometriosis diagnosis after symptoms start [3] Menstrual Cycle & Health - Irregular menstrual cycles should be a cause for concern [1] - Lack of a period is harmful to long-term health, brain health, mental health, low energy, mood, and libido [1] Women's Health Discussions & Education - There is a lack of public discussion and education regarding women's health issues [2][3][4] - Patients often normalize pain, delaying diagnosis and treatment [4]

Core Insights - Knight Therapeutics Inc. has relaunched MYFEMBREE, a treatment for uterine fibroids and endometriosis, in Canada, enhancing its women's health portfolio [1][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7]. Product Details - MYFEMBREE is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, approved by Health Canada in September 2023, and is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women [3][4]. - The total sales for gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist products for endometriosis and uterine fibroids in Canada are estimated at $45 million, with a five-year CAGR of 8% [3]. Market Context - Uterine fibroids affect 20-30% of women of reproductive age, with 70-80% detected by age 50, often leading to symptoms like heavy menstrual bleeding and pelvic pain [5]. - Endometriosis affects approximately 10% of reproductive-aged women globally, with significant diagnostic delays and limited treatment options available [6].